Table S1.
Patients | Clinical measurements | |||||
MCV, fL | MCHC, g/dL | HbS, % | HbF, % | HbA, % | HbA2, % | |
On-drug | ||||||
Patient I | 108 | 36 | 61.4 | 33.0 | 2.9 | 2.6 |
Patient II | 95 | 33 | 79.3 | 13.2 | 2.8 | 4.7 |
Patient III | 84 | 30 | 89.3 | 4.4 | 1.5 | 4.7 |
Patient IV | 75 | 37 | 80.7 | 11.7 | 2.5 | 5.1 |
Patient V | 131 | 36 | 81.8 | 11.8 | 2.3 | 4.1 |
Off-drug | ||||||
Patient VI | 97 | 32 | 84.5 | 4.3 | 6.1 | 5.1 |
Patient VII | 98 | 36 | 84.7 | 8.2 | 2.4 | 4.8 |
Patient VIII | 83 | 38 | 84.7 | 8.2 | 2.4 | 4.8 |
Patient IX | 84 | 36 | 84.9 | 7.8 | 2.5 | 4.8 |
Patient X | 83 | 36 | 84.3 | 8.5 | 2.2 | 5.1 |
Patient XI | 70 | 36 | 73.0 | 20.6 | 2.9 | 3.5 |
MCV and MCHC have been obtained from complete blood count (CBC) analysis from clinical measurements. Blood composition data are extracted from gel electrophoresis experiments identifying the fraction of various Hb types in patients in this study (n = 11).